Impact of Chronic Pre-Treatment of Statins on the Level of Systemic Inflammation and Myocardial Perfusion in Patients Undergoing Primary Angioplasty

Oduncu, Vecih; Tanalp, Ali Cevat; Erkol, Ayhan; Sırma, Dicle; Dündar, Cihan; Akgün, Taylan; Türkyılmaz, Erdem; Kılıçgedik, Alev; Gözübüyük, Gökhan; Tigen, Kürşat; Izgi, Akin; Kırma, Cevat

doi:10.1016/j.amjcard.2010.09.008

Cited by 28 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Oduncu et al [26] showed that in STEMI patients treated with PCI, basal CRP levels were higher in patients developing no-reflow, whereas previous use of statins decreased the incidence of no-reflow.…”

Section: Discussionmentioning

confidence: 95%

Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction

Kurtul

Yarlıoğlueş

Çelik

et al. 2015

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction

Kurtul

Yarlıoğlueş

Çelik

et al. 2015

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

“…No obvious differences on the baseline characteristics comparison were observed between these subgroups and the control group . Although relevant data of the included patients in the study by Oduncu et al were not available, lipid levels including low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, total cholesterol, and triglyceride of the patients on admission were mentioned, which revealed no obvious differences between the 2 groups . There were no significant differences with respect to most of the demographic and clinical parameters between the statin pretreatment group and the control group.…”

Section: Resultsmentioning

confidence: 94%

“…Of the 15 studies, two studies were excluded for having no data on myocardial perfusion status, and 1 study was excluded for myocardial perfusion status assessed by intracoronary myocardial contrast echocardiography . Finally, twelve studies meeting inclusion/exclusion criteria were retained in the analysis, of which 9 were cohort studies, and 3 were RCTs …”

Section: Resultsmentioning

confidence: 99%

Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta‐analysis

Lyu

Zhao

Zhang

et al. 2013

Clinical Cardiology

View full text Add to dashboard Cite

Background: To achieve sufficient myocardial perfusion in ST-segment elevation myocardial infarction (STEMI) patients receiving primary percutaneous coronary intervention (PPCI), many adjunctive therapies have been proposed. Previous trials have reported variances in myocardial perfusion improvement for statin pretreatment, which made it inconvincible to confirm the beneficial effects of statins. Therefore, we performed a systematic review and meta-analysis to determine whether statin pretreatment was effective in improving myocardial perfusion. Hypothesis: Statin pretreatment could improve myocardial perfusion in STEMI patients undergoing PPCI. Methods: We searched the PubMed, Web of Knowledge, and the Cochrane Library databases for studies evaluating the impact of statin pretreatment on myocardial perfusion in STEMI patients receiving PPCI. Results: Twelve trials were finally included in our meta-analysis. There were no significant differences in patients' baseline characteristics between the statin pretreatment and control groups. Overall pooled analysis showed that patients in the statin pretreatment groups had significantly better epicardial coronary blood flow (measured by Thrombosis in Myocardial Infarction [TIMI] grade, odds ratio [OR]: 0.49, 95% confidence interval [CI]: 0.28 to 0.84; measured by corrected TIMI frame count, mean difference: −5.63; 95% CI: −9.66 to −1.6). A trend toward myocardial tissue level perfusion improvement was seen in the statin pretreatment arm rather than the control arm (measured by myocardial blush grade, OR: 0.74; 95% CI: 0.50 to 1.09).Conclusions: This present meta-analysis suggests that statin pretreatment might be effective in improving myocardial perfusion in STEMI patients.

show abstract

“…One of the most possible underlying mechanisms linking serum PCT level and no-reflow may be increased inflammatory activity. Many previous studies have confirmed the association between systemic inflammation and the no-reflow phenomenon [25,26]. Akpek et al [27] reported that the neutrophil to lymphocyte ratio and CRP had a significant and positive correlation with no-reflow in patients with STEMI after PPCI.…”

Section: Discussionmentioning

confidence: 89%

The association of serum procalcitonin level with the no-reflow phenomenon after a primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction

Murat

Kurtul

Çelik

et al. 2016

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

Impact of Chronic Pre-Treatment of Statins on the Level of Systemic Inflammation and Myocardial Perfusion in Patients Undergoing Primary Angioplasty

Cited by 28 publications

References 28 publications

Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction

Association of lymphocyte-to-monocyte ratio with the no-reflow phenomenon in patients who underwent a primary percutaneous coronary intervention for ST-elevation myocardial infarction

Effect of Statin Pretreatment on Myocardial Perfusion in Patients Undergoing Primary Percutaneous Coronary Intervention: A Systematic Review and Meta‐analysis

The association of serum procalcitonin level with the no-reflow phenomenon after a primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction

Contact Info

Product

Resources

About